EMA approves Moderna vaccine for ages 12 and up

THE HAGUE: The European medicines watchdog on Friday approved the use of Moderna’s coronavirus vaccine for children aged 12 to 17, making it the second jab for adolescents for use on the continent.

“The use of the Spikevax vaccine in children from 12 to 17 years of age will be the same as in people aged 18 and above,” the European Medicines Agency ( EMA) said, using the vaccine’s brand name.

The vaccine will be given in two injections, each four weeks apart.

The decision by the Amsterdam-based agency follows the approval of the first vaccine for European youngsters, by Pfizer/biontech in May.

The effects of the jab have been studied among 3,732 children aged 12 to 17 years, the EMA said.

“The study showed that Spikevax produced a comparable antibody response in 12- to 17-yearolds to that seen in young adults aged 18 to 25 years,” it said. The Moderna jab employs the same MRNA technology as Pfizer/biontech, using genetic material to deliver instructions to human cells to create coronavirus spike proteins.

It thereby trains an immune response without exposing the host to a real infection.

The EMA said there were common side effects in children similar to those in adults.

This included pain and swelling at the injection site, tiredness, headache, muscle and joint pain, enlarged lymph nodes, chills, nausea, vomiting and fever.

“These effects are usually mild or moderate and improve within a few days from the vaccination,” the EMA said.

But it noted that due to the “limited number of children and adolescents included in the study, the trial could not have detected new uncommon side effects.”

Nor could it estimate the risk of known side effects such as myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the membrane around the heart).

“However, the overall safety profile of Spikevax determined in adults was confirmed in the adolescent study,” it said.